On Tuesday, Cue Biopharma Inc (NASDAQ: CUE) opened lower -1.82% from the last session, before settling in for the closing price of $1.10. Price fluctuations for CUE have ranged from $0.45 to $3.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 163.36%. Company’s average yearly earnings per share was noted 33.69% at the time writing. With a float of $62.88 million, this company’s outstanding shares have now reached $63.35 million.
Let’s determine the extent of company efficiency that accounts for 53 employees. In terms of profitability, gross margin is -17.81%, operating margin of -477.77%, and the pretax margin is -468.02%.
Cue Biopharma Inc (CUE) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cue Biopharma Inc is 0.74%, while institutional ownership is 23.54%.
Cue Biopharma Inc (CUE) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.29 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.28) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 33.69% per share during the next fiscal year.
Cue Biopharma Inc (NASDAQ: CUE) Trading Performance Indicators
Check out the current performance indicators for Cue Biopharma Inc (CUE). In the past quarter, the stock posted a quick ratio of 2.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.91, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Cue Biopharma Inc (CUE)
Looking closely at Cue Biopharma Inc (NASDAQ: CUE), its last 5-days average volume was 0.93 million, which is a jump from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 3.40%. Additionally, its Average True Range was 0.26.
During the past 100 days, Cue Biopharma Inc’s (CUE) raw stochastic average was set at 40.93%, which indicates a significant increase from 4.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 134.61% in the past 14 days, which was lower than the 152.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1596, while its 200-day Moving Average is $1.3857. However, in the short run, Cue Biopharma Inc’s stock first resistance to watch stands at $1.1667. Second resistance stands at $1.2533. The third major resistance level sits at $1.3167. If the price goes on to break the first support level at $1.0167, it is likely to go to the next support level at $0.9533. Now, if the price goes above the second support level, the third support stands at $0.8667.
Cue Biopharma Inc (NASDAQ: CUE) Key Stats
There are currently 48,643K shares outstanding in the company with a market cap of 68.42 million. Presently, the company’s annual sales total 5,490 K according to its annual income of -50,730 K. Last quarter, the company’s sales amounted to 3,340 K and its income totaled -8,660 K.
